Benralizumab

Benralizumab

Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.

 

 

[accordions]
[accordion title= “Chemical Properties“]

Synonyms MEDI-563, BIW-8405
Molecular Weight N/A
CAS No. 1044511-01-4

[/accordion]

 

 

 

[accordions]
[accordion title= “References and Literature“]

1. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019.

[/accordion]